InMed Pharmaceuticals Inc.

(1) Eric A. Adams’ beneficial ownership consists of 2,197 Common Shares owned directly and 5,696 Common Shares issuable pursuant to presently exercisable options. Not reflected in the table are 29 Common Shares beneficially owned by Mr. Adams’ spouse. Mr. Adams disclaims beneficial ownership of the 29 Common Shares held by his spouse.

(2) Andrew Hull’s beneficial ownership consists of 1,912 Common Shares owned directly and 425 Common Shares issuable pursuant to presently exercisable options.

(3) Bryan Baldasare’s beneficial ownership consists of 425 Common Shares issuable pursuant to presently exercisable options.

(4) Nicole Lemerond’s beneficial ownership consists of 425 Common Shares issuable pursuant to presently exercisable options.

(5) Eric Hsu’s beneficial ownership consists of 2 Common Shares owned directly. and 1,946 Common Shares issuable pursuant to presently exercisable options.

(6) Michael Woudenberg’s beneficial ownership consists of 1 Common Share owned directly and 2,765 Common Shares issuable pursuant to presently exercisable options.

(7) Netta Jagpal’s beneficial ownership consists of 1,750 Common Shares issuable pursuant to presently exercisable options.

(8) As of April 29, 2025, Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, or the Armistice Fund, beneficially owned (along with Steven Boyd, the Managing Member of Armistice Capital (defined below)) 4.99% of our issued and outstanding Common Shares. Such information is based solely on the Schedule 13G/A filed by the Armistice Fund with the SEC on November 14, 2024. The address of the Armistice Fund is 510 Madison Avenue, 7 th Floor, New York, New York 10022. The Armistice Fund has the right to acquire 278,761 Common Shares issuable upon presently exercisable Preferred Investment Options (as discussed below in this footnote 8). The Preferred Investment Options are directly held by Armistice Fund and may be deemed to be indirectly beneficially owned by (i) Armistice Capital, LLC, or Armistice Capital, as the investment manager of Armistice Fund, and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

As of April 29, 2025, Sabby Volatility Warrant Master Fund, Ltd. (“Sabby Fund”) beneficially owns 36,135 Common Shares and maintains the right to acquire an additional 199,114 Common Shares issuable upon presently exercisable Preferred Investment Options (as discussed below in this footnote 8). Sabby Management, LLC (“Sabby Management”) is the investment manager of Sabby Fund and shares voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, Hal Mintz also shares voting and investment power on behalf of Sabby Fund.

Each of Sabby Fund and Armistice Fund currently hold Preferred Investment Options in the Company entitling them to acquire Common Shares that may exceed the 5% threshold; however, the terms of the Preferred Investment Options preclude a holder thereof from exercising such holder’s preferred investment option, if after giving effect to the issuance of Common Shares upon such exercise, the holder (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) would beneficially own in excess of 4.99% (or, upon election by a holder prior to the issuance of any preferred investment options, 9.99% with effect not sooner than 61 days after notifying the Company) of the number of Common Shares outstanding immediately after giving effect to the issuance of Common Shares issuable upon such exercise.